NG2/HMP proteoglycan as a cancer therapeutic target

Methods in Molecular Biology

Volumn 361, Issue , 2007, Pages 93-117

  Chekenya, Martha ^a   Immervoll, Heike ^a  

^a NONE

Author keywords

Glioma; Immunotherapy; Melanoma; NG2; siRNA

Indexed keywords

ANTIGEN; ANTINEOPLASTIC AGENT; CHONDROITIN SULFATE PROTEOGLYCAN 4; PROTEOGLYCAN; SIGNAL PEPTIDE;

ANIMAL; BRAIN TUMOR; CELL ADHESION; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL MOTION; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; EXTRACELLULAR MATRIX; GLIA; HUMAN; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NERVE CELL; PATHOLOGY; REVIEW; STROMA CELL;

ANIMALS; ANTIGENS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL ADHESION; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; EXTRACELLULAR MATRIX; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; NEUROGLIA; NEURONS; PROTEOGLYCANS; STROMAL CELLS;

EID: 36549040918     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1385/1-59745-208-4:93     Document Type: Article

References (159)

1. Rutka, J. T., Apodaca, G., Stern, R., and Rosenblum, M. (1988) The extracellular matrix of the central and peripheral nervous systems: structure and function. J. Neurosurg. 69, 155-170.
2. Tillet, E., Ruggiero, E, Nishiyama, A., and Stallcup, W. B. (1997) The membrane-spanning proteoglycan NG2 binds to collagens V and VI through the central nonglobular domain of its core protein. J. Biol. Chem. 272, 10,769-10,776.
3. Burg, M. A., Nishiyama, A., and Stallcup, W. B. (1997) A central segment of the NG2 proteoglycan is critical for the ability of glioma cells to bind and migrate toward type VI collagen. Exp. Cell Res., 235, 254-264.
4. Schlessinger, J., Lax, I., and Lemmon, M. (1995) Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors? Cell, 83, 357-360.
5. David, G. (1993) Integral membrane heparan sulfate proteoglycans. FASEB J. 7, 1023-1030.
6. Stallcup, W. B. (2002) The NG2 proteoglycan: past insights and future prospects. /. Neurocytol. 31, 423-435.
7. Stallcup, W. B., and Dahlin-Huppe, K. (2001) Chondroitin sulfate and cytoplasmic domain-dependent membrane targeting of the NG2 proteoglycan promotes retraction fiber formation and cell polarization. J. Cell Sci. 114, 2315-2325.
8. Nishiyama, A., Lin, X. H., and Stallcup, W. B. (1995) Generation of truncated forms of the NG2 proteoglycan by cell surface proteolysis. Mol. Biol. Cell 6, 1819-1832.
9. Yamaguchi, Y. (2000) Chondroitin sulfate proteoglycans in the nervous system. Marcel Dekker, Inc., New York.
10. Yamaguchi, Y. (2001) Heparin sulfate proteoglycans in the nervous system: Their diverse roles in neurogenesis.axon guidance, and synaptogenesis. Sem. Cell Dev. Biol. 12, 96-106.
11. Songyang, Z., Fanning, A. S., Fu, C., et al. (1997) Recognition of unique carboxyl-terminal motifs by distinct PDZ domains. Science 275, 73-77.
12. Barritt, D. S., Pearn, M. T., Zisch, A. H., et al. (2000) The multi-PDZ domain protein MUPP1 is a cytoplasmic ligand for the membrane-spanning proteoglycan NG2. J. Cell Biochem. 79, 213-224.
13. Nishiyama, A., Dahlin, K. J., Prince, J. T., Johnstone, S. R., and Stallcup, W. B. (1991) The primary structure of NG2, a novel membrane-spanning proteoglycan. J. Cell Biol. 114, 359-371.
14. Yu, H., Chen, J. K., Feng, S., Dalgarno, D. C., Brauer, A. W., and Schreiber, S. L. (1994) Structural basis for the binding of proline-rich peptides to SH3 domains. Cell 76, 933-945.
15. Stallcup, W. B., Beasley, L. and Levine, J. (1983) Cell-surface molecules that characterize different stages in the development of cerebellar interneurons. Cold Spring Harb Symp. Quant. Biol. 48 Pt 2, 761-774.
16. Houghton, A. N., Eisinger, M., Albino, A. P., Cairncross, J. G., and Old, L. J. (1982) Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J. Exp. Med., 156, 1755-1766.
17. Bumol, T. F., Walker, L. E., and Reisfeld, R. A. (1984) Biosynthetic studies of proteoglycans in human melanoma cells with a monoclonal antibody to a core glycoprotein of chondroitin sulfate proteoglycans. J. Biol. Chem., 259, 12, 733-12,741.
18. Bumol, T. F. and Reisfeld, R. A. (1982) Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells. Proc. Natl. Acad. Sci. USA 79, 1245-1249.
19. Schneider, S., Bosse, F., D'Urso, D., et al. (2001) The AN2 protein is a novel marker for the Schwann cell lineage expressed by immature and nonmyelinating Schwann cells. J. Neurosci., 21, 920-933.
20. Niehaus, A., Stegmuller, J., Diers-Fenger, M., and Trotter, J. (1999) Cell-surface glycoprotein of oligodendrocyte progenitors involved in migration. J. Neurosci. 19, 4948-4961.
21. Trapp, B. D., Nishiyama, A., Cheng, D., and Macklin, W. (1997) Differentiation and death of premyelinating oligodendrocytes in developing rodent brain. J. Cell Biol. 137, 459-468.
22. Reynolds, R. and Hardy, R. (1997) Oligodendroglial progenitors labeled with the 04 antibody persist in the adult rat cerebral cortex in vivo. J. Neurosci. Res. 47, 455-470.
23. Nishiyama, A., Lin, X. H., Giese, N., Heldin, C. H., and Stallcup, W. B. (1996) Interaction between NG2 proteoglycan and PDGF alpha-receptor on O2A progenitor cells is required for optimal response to PDGE J. Neurosci. Res., 43, 315-330.
24. Nishiyama, A., Lin, X. H., Giese, N., Heldin, C. H., and Stallcup, W. B. (1996) Co-localization of NG2 proteoglycan and PDGF alpha-receptor on O2A progenitor cells in the developing rat brain. J. Neurosci. Res., 43, 299-314.
25. Levine, J. M., Stincone, F., and Lee, Y. S. (1993) Development and differentiation of glial precursor cells in the rat cerebellum. Glia, 7, 307-321.
26. Keirstead, H. S., Levine, J. M., and Blakemore, W. E (1998) Response of the oligodendrocyte progenitor cell population (defined by NG2 labelling) to demyelination of the adult spinal cord. Gliaa 22, 161-170.
27. Luskin, M. B., Parnavelas, J. G., and Barfield, J. A. (1993) Neurons, astrocytes, and oligodendrocytes of the rat cerebral cortex originate from separate progenitor cells: an ultrastructural analysis of clonally related cells. J. Neurosci. 13, 1730-1750.
28. Levison, S. W., Young, G. M., and Goldman, J. E. (1999) Cycling cells in the adult rat neocortex preferentially generate Oligodendroglia. J. Neurosci. Res. 57, 435-446.
29. Levison, S. W. and Goldman, J. E. (1993) Both oligodendrocytes and astrocytes develop from progenitors in the subventricular zone of postnatal rat forebrain. Neuron 10, 201-212.
30. Grove, E. A., Williams, B. P., Li, D. Q., Hajihosseini, M., Friedrich, A. and Price, J. (1993) Multiple restricted lineages in the embryonic rat cerebral cortex. Development 117, 553-561.
31. Richardson, W D., Pringle, N., Mosley, M. J., Westermark, B., and Dubois-Dalcq, M. (1988) A role for platelet-derived growth factor in normal gliogenesis in the central nervous system. Cell, 53, 309-319.
32. Raff, M. C., Lillien, L. E., Richardson, W D., Burne, J. F., and Noble, M. D. (1988) Platelet-derived growth factor from astrocytes drives the clock that times oligodendrocyte development in culture. Nature 333, 562-565.
33. Ellison, J. A. and de Vellis, J. (1994) Platelet-derived growth factor receptor is expressed by cells in the early oligodendrocyte lineage. J. Neurosci. Res. 37, 116-128.
34. Tanaka, K., Nogawa, S., Ito, D., et al. (2001) Activation of NG2-positive oligodendrocyte progenitor cells during post-ischemic reperfusion in the rat brain. Neuroreport 12, 2169-2174.
35. Levine, J. M., Reynolds, R., and Fawcett, J. W. (2001) The oligodendrocyte precursor cell in health and disease. Trends Neurosci. 24, 39-47.
36. Shee, W. L., Ong, W. Y., and Lim, T. M. (1998) Distribution of perlecan in mouse hippocampus following intracerebroventricular kainate injections. Brain Res. 799, 292-300.
37. Reynolds, R., Cenci di Bello, I., Dawson, M., and Levine, J. (2001) The response of adult oligodendrocyte progenitors to demyelination in EAE. Prog. Brain Res. 132, 165-174.
38. McTigue, D. M., Wei, P., and Stokes, B. T. (2001) Proliferation of NG2-positive cells and altered oligodendrocyte numbers in the contused rat spinal cord. J. Neurosci. 21, 3392-3400.
39. Levine, J. M., Enquist, L. W., and Card, J. P. (1998) Reactions of oligodendrocyte precursor cells to alpha herpesvirus infection of the central nervous system. Glia 23, 316-328.
40. Levine, J. M. (1994) Increased expression of the NG2 chondroitin-sulfate proteoglycan after brain injury. J. Neurosci., 14, 4716-4730.
41. Back, S. A., Luo, N. L., Borenstein, N. S., Levine, J. M., Volpe, J. J., and Kinney, H. C. (2001) Late oligodendrocyte progenitors coincide with the developmental window of vulnerability for human perinatal white matter injury. J. Neurosci. 21, 1302-1312.
42. Jones, L. L., Yamaguchi, Y., Stallcup, W. B., and Tuszynski, M. H. (2002) NG2 is a major chondroitin sulfate proteoglycan produced after spinal cord injury and is expressed by macrophages and oligodendrocyte progenitors. J. Neurosci. 22, 2792-2803.
43. Humphries, M. J. (2000) Integrin cell adhesion receptors and the concept of agonism. Trends Pharmacol. Sci. 21, 29-32.
44. Garrigues, H. J., Lark, M. W, Lara, S., Hellstrom, L, Hellstrom, K. E., and Wight, T. N. (1986) The melanoma proteoglycan: restricted expression on microspikes, a specific microdomain of the cell surface. J. Cell Biol. 103, 1699-1710.
45. Harper, J. R., Bumol, T. F., and Reisfeld, R. A. (1984) Characterization of monoclonal antibody 155.8 and partial characterization of its proteoglycan antigen on human melanoma cells. J. Immunol. 132, 2096-2104.
46. de Vries, J. E., Keizer, G. D., te Velde, A. A., et al. (1986) Characterization of melanoma-associated surface antigens involved in the adhesion and motility of human melanoma cells. Int. J. Cancer 38, 465-473.
47. Fukushi, J., Makagiansar, I. T., and Stallcup, W. B. (2004) NG2 proteoglycan promotes endothelial cell motility and angiogenesis via engagement of galectin-3 and alpha3beta1 integrin. Mol. Biol. Cell 15, 3580-3590.
48. Gladson, C. L. (1999) The extracellular matrix of gliomas: modulation of cell function. J. Neuropathol. Exp. Neurol. 58, 1029-1040.
49. Burg, M. A., Grako, K. A., and Stallcup, W. B. (1998) Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells. J. Cell Physiol. 177, 299-312.
50. East, J. A., Mitchell, S. D., and Hart, I. R. (1993) Expression and function of the CD44 glycoprotein in melanoma cell lines. Melanoma Res. 3, 341-346.
51. Kuppner, M. C., Van Meir, E., Gauthier, T., Hamou, M. F., and de Tribolet, N. (1992) Differential expression of the CD44 molecule in human brain tumours. Int., J. Cancer 50, 572-577.
52. Merzak, A., Koocheckpour, S., and Pilkington, G. J. (1994) CD44 mediates human glioma cell adhesion and invasion in vitro. Cancer Res. 54, 3988-3992.
53. Akiyama, Y., Jung, S., Salhia, B., et al. (2001) Hyaluronate receptors mediating glioma cell migration and proliferation. J. Neurooncol. 53, 115-127.
54. Midwood, K. S. and Salter, D. M. (2001) NG2/HMPG modulation of human articular chondrocyte adhesion to type VI collagen is lost in osteoarthritis. J. Pathol. 195, 631-635.
55. Iida, J., Meijne, A. M., Spiro, R. C., Roos, E., Furcht, L. T., and McCarthy, J. B. (1995) Spreading and focal contact formation of human melanoma cells in response to the stimulation of both melanoma-associated proteoglycan (NG2) and alpha 4 beta 1 integrin. Cancer Res. 55, 2177-2185.
56. Doane, K. J., Howell, S. J., and Birk, D. E. (1998) Identification and functional characterization of two type VI collagen receptors, alpha 3 beta 1 integrin and NG2, during avian corneal stromal development. Invest. Ophthalmol. Vis. Sci. 39, 263-275.
57. Burg, M. A., Tillet, E., Timpl, R., and Stallcup, W. B. (1996) Binding of the NG2 proteoglycan to type VI collagen and other extracellular matrix molecules. J. Biol. Chem. 271, 26, 110-26,116.
58. Nishiyama, A. and Stallcup, W. B. (1993) Expression of NG2 proteoglycan causes retention of type VI collagen on the cell surface. Mol. Biol. Cell 4, 1097-1108.
59. Stallcup, W. B., Dahlin, K., and Healy, P. (1990) Interaction of the NG2 chondroitin sulfate proteoglycan with type VI collagen. J. Cell Biol., 111, 3177-3188.
60. Kuo, H. J., Maslen, C. L., Keene, D. R., and Glanville, R. W. (1997) Type VI collagen anchors endothelial basement membranes by interacting with type IV collagen. J. Biol. Chem. 272, 26, 522-26,529.
61. Rand, J. H., Wu, X. X., Potter, B. J., Uson, R. R., and Gordon, R. E. (1993) Colocalization of von Willebrand factor and type VI collagen in human vascular subendothelium. Am. J. Pathol. 142, 843-850.
62. Chintala, S. K., Sawaya, R., Gokaslan, Z. L., Fuller, G., and Rao, J. S. (1996) Immunohistochemical localization of extracellular matrix proteins in human glioma, both in vivo and in vitro. Cancer Lett. 101, 107-114.
63. Paulus, W., Roggendorf, W., and Schuppan, D. (1988) Immunohistochemical investigation of collagen subtypes in human glioblastomas. Virchows Arch. A Pathol. Anat. Histopathol. 413, 325-332.
64. Chekenya, M., Rooprai, H. K., Davies, D., Levine, J. M., Butt, A. M., and Pilkington, G. J. (1999) The NG2 chondroitin sulfate proteoglycan: role in malignant progression of human brain tumours. Int J. Dev. Neurosci. 17, 421-435.
65. Chekenya, M., Enger, P., Thorsen, F., et al. (2002) The glial precursor proteoglycan, NG2, is expressed on tumour neovasculature by vascular pericytes in human malignant brain tumours. Neuropathol. Appl. Neurobiol. 28, 367-380.
66. Lemmon, V., Farr, K. L., and Lagenaur, C. (1989) L1-mediated axon outgrowth occurs via a homophilic binding mechanism. Neuron 2, 1597-1603.
67. Edgar, D., Timpl, R., and Thoenen, H. (1984) The heparin-binding domain of laminin is responsible for its effects on neurite outgrowth and neuronal survival. EMBO J. 3, 1463-1468.
68. Fidler, P. S., Schuette, K., Asher, R. A., et al. (1999) Comparing astrocytic cell lines that are inhibitory or permissive for axon growth: the major axon-inhibitory proteoglycan is NG2. J. Neurosci. 19, 8778-8788.
69. Fawcett, J. W., and Asher, R. A. (1999) The glial scar and central nervous system repair. Brain Res. Bull 49, 377-391.
70. Dou, C. L., and Levine, J. M. (1994) Inhibition of neurite growth by the NG2 chondroitin sulfate proteoglycan. J. Neurosci. 14, 7616-7628.
71. Pedersen, P. H., Marienhagen, K., Mork, S., and Bjerkvig, R. (1993) Migratory pattern of fetal rat brain cells and human glioma cells in the adult rat brain. Cancer Res. 53, 5158-5165.
72. Giordana, M. T., Germano, I., Giaccone, G., Mauro, A., Migheli, A., and Schiffer, D. (1985) The distribution of laminin in human brain tumors: an immunohistochemical study. Acta. NeuroPathol. (Berl) 67, 51-57.
73. Noble, M. -P. (2001) Glial Restricted Precursors. Humana Press, Totowa, New Jersey.
74. Sugimoto, Y., Taniguchi, M., Yagi, T., Akagi, Y., Nojyo, Y., and Tamamaki, N. (2001) Guidance of glial precursor cell migration by secreted cues in the developing optic nerve. Development 128, 3321-3330.
75. Fang, X., Burg, M. A., Barritt, D., Dahlin-Huppe, K., Nishiyama, A., and Stallcup, W. B. (1999) Cytoskeletal reorganization induced by engagement of the NG2 proteoglycan leads to cell spreading and migration. Mol. Biol. Cell 10, 3373-3387.
76. Lin, X. H., Dahlin-Huppe, K., and Stallcup, W. B. (1996) Interaction of the NG2 proteoglycan with the actin cytoskeleton. J. Cell Biochem. 63, 463-477.
77. Bogler, O., Wren, D., Barnett, S. C., Land, H., and Noble, M. (1990) Cooperation between two growth factors promotes extended self-renewal and inhibits differentiation of oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells. Proc. Natl. Acad. Sci. USA 87, 6368-6372.
78. Baron, W, Metz, B., Bansal, R., Hoekstra, D., and de Vries, H. (2000) PDGF and FGF-2 signaling in oligodendrocyte progenitor cells: regulation of proliferation and differentiation by multiple intracellular signaling pathways. Mol. Cell Neurosci. 15, 314-329.
79. Redwine, J. M., Blinder, K. L., and Armstrong, R. C. (1997) In situ expression of fibroblast growth factor receptors by oligodendrocyte progenitors and oligodendrocytes in adult mouse central nervous system. J. Neurosci. Res. 50, 229-237.
80. Grako, K. A., and Stallcup, W. B. (1995) Participation of the NG2 proteoglycan in rat aortic smooth muscle cell responses to platelet-derived growth factor. Exp. Cell Res. 221, 231-240.
81. Goretzki, L., Burg, M. A., Grako, K. A., and Stallcup, W. B. (1999) High-affinity binding of basic fibroblast growth factor and platelet-derived growth factor-AA to the core protein of the NG2 proteoglycan. J. Biol. Chem. 274, 16,831-16,837.
82. Brekke, C., Lundervold, A., Enger, P. O., et al. (2006) NG2 expression regulates vascular morphology and function in human brain tumours. NeuroImage 29, 965-976. Epub Oct 25, 2005.
83. Chekenya, M., Hjelstuen, M., Enger, P. O., et al. (2002) NG2 proteoglycan promotes angiogenesis-dependent tumor growth in CNS by sequestering angiostatin. FASEB J. 16, 586-588.
84. Hermanson, M., Funa, K., Koopmann, J., et al. (1996) Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas. Cancer Res. 56, 164-171.
85. Nister, M., Libermann, T. A., Betsholtz, C., et al. (1988) Expression of messenger RNAs for platelet-derived growth factor and transforming growth factoralpha and their receptors in human malignant glioma cell lines. Cancer Res. 48, 3910-3918.
86. Fleming, T. P., Saxena, A., Clark, W. C., et al. (1992) Amplification and/or over-expression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res. 52, 4550-4553.
87. Bergers, G., and Benjamin, L. E. (2003) Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3, 401-410.
88. Ozerdem, U., Monosov, E., and Stallcup, W B. (2002) NG2 Proteoglycan Expression by Pericytes in Pathological Microvasculature. Microvasc. Res. 63, 129-134.
89. Ozerdem, U., Grako, K. A., Dahlin-Huppe, K., Monosov, E., and Stallcup, W. B. (2001) NG2 proteoglycan is expressed exclusively by mural cells during vascular morphogenesis. Dev. Dyn 111, 218-227.
90. Miller, B., Sheppard, A. M., Bicknese, A. R., and Pearlman, A. L. (1995) Chondroitin sulfate proteoglycans in the developing cerebral cortex: the distribution of neurocan distinguishes forming afferent and efferent axonal pathways. J. Comp. Neurol. 355, 615-628.
91. Lindahl, P., Johansson, B. R., Leveen, P., and Betsholtz, C. (1997) Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 111, 242-245.
92. Hellstrom, M., Kalen, M., Lindahl, P., Abramsson, A., and Betsholtz, C. (1999) Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126, 3047-3055.
93. Murfee, W. L., Skalak, T. C., and Peirce, S. M. (2005) Differential arterial/venous expression of NG2 proteoglycan in perivascular cells along microvessels: identifying a venule-specific phenotype. Microcirculation 12, 151-160.
94. Schwartz, S. M., Heimark, R. L., and Majesky, M. W. (1990) Developmental mechanisms underlying pathology of arteries. Physiol. Rev. 70, 1177-1209.
95. Ross. (1993) The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362, 801-809.
96. Grako, K. A., Ochiya, T., Barritt, D., Nishiyama, A., and Stallcup, W. B. (1999) PDGF (alpha)-receptor is unresponsive to PDGF-AA in aortic smooth muscle cells from the NG2 knockout mouse. J. Cell Sci. 112 (Pt 6), 905-915.
97. Orlidge, A., and D'Amore, P. A. (1987) Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells. J. Cell Biol. 105, 1455-1462.
98. Asher, R. A., Morgenstern, D. A., Properzi, F., Nishiyama, A., Levine, J. M., and Fawcett, J. W (2005) Two separate metalloproteinase activities are responsible for the shedding and processing of the NG2 proteoglycan in vitro. Mol. Cell Neurosci. 29, 82-96.
99. Goretzki, L., Lombardo, C. R., and Stallcup, W. B. (2000) Binding of the NG2 proteoglycan to kringle domains modulates the functional properties of angiostatin and plasmin(ogen). J. Biol. Chem. 275, 28,625-28,633.
100. Ashley, D. M., Batra, S. K., and Bigner, D. D. (1997) Monoclonal antibodies to growth factors and growth factor receptors: their diagnostic and therapeutic potential in brain tumors. J. Neurooncol. 35, 259-273.
101. Harper, J. R., and Reisfeld, R. A. (1983) Inhibition of anchorage-independent growth of human melanoma cells by a monoclonal antibody to a chondroitin sulfate proteoglycan. J. Natl. Cancer Inst. 71, 259-263.
102. Bumol, T. E, Wang, Q. C., Reisfeld, R. A., and Kaplan, N. O. (1983) Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth. Proc. Natl. Acad. Sci. USA 80, 529-533.
103. Folkman, J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27-31.
104. Burrows, E J., and Thorpe, P. E. (1993) Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc. Natl. Acad. Sci. USA 90, 8996-9000.
105. Kerbel, R. S. (1997) A cancer therapy resistant to resistance. Nature 390, 335-336.
106. Kerbel, R. S. (1991) Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 13, 31-36.
107. Boehm, T., Folkman, J., Browder, T., and O'Reilly, M. S. (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404-407.
108. Natali, P. G., Imai, K., Wilson, B. S., et al. (1981) Structural properties and tissue distribution of the antigen recognized by the monoclonal antibody 653.40S to human melanoma cells. J. Natl. Cancer Inst. 67, 591-601.
109. Ferrone, S. G. P., Natali, P. G., et al. (1983) A human high molecular weightmelanoma associated antigen (HMWW_MAA) defined by monoclonal antibodies: a useful marker to radioimage tumor lesions in patients with melanoma. Brookhaven National Laboratories. Associated Universities, Inc., Brookhaven, New York.
110. Giacomini, P., Natali, P., and Ferrone, S. (1985) Analysis of the interaction between a human high molecular weight melanoma-associated antigen and the monoclonal antibodies to three distinct antigenic determinants. J. Immunol. 135, 696-702.
111. Lindmo, T., Boven, E., Cuttitta, F., Fedorko, J., and Bunn, P. A., Jr. (1984) Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods 72, 77-89.
112. Kohler, G., and Milstein, C. (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497.
113. Winter, G., Griffiths, A. D., Hawkins, R. E., and Hoogenboom, H. R. (1994) Making antibodies by phage display technology. Annu. Rev. Immunol. 12, 433-455.
114. Schaffitzel, C., Hanes, J., Jermutus, L., and Pluckthun, A. (1999) Ribosome display: an in vitro method for selection and evolution of antibodies from libraries. J. Immunol. Methods 231, 119-135.
115. Giovannoni, L., Viti, F., Zardi, L., and Neri, D. (2001) Isolation of anti-angiogenesis antibodies from a large combinatorial repertoire by colony filter screening. Nucleic Acids Res. 29, E27.
116. Graff, C. P., Chester, K., Begent, R., and Wittrup, K. D. (2004) Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 degrees C. Protein Eng. Des. Sel. 17, 293-304.
117. Olafsen, T., Tan, G. J., Cheung, C. W., et al. (2004) Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Eng. Des. Sel. 17, 315-323.
118. Epenetos, A. A., Snook, D., Durbin, H., Johnson, P. M., and Taylor-Papadimitriou, J. (1986) Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Res. 46, 3183-3191.
119. Neuwelt, E. A., Specht, H. D., Barnett, P. A., et al. (1987) Increased delivery of tumor-specific monoclonal antibodies to brain after osmotic blood-brain barrier modification in patients with melanoma metastatic to the central nervous system. Neurosurgery 20, 885-895.
120. Jain, R. K., and Baxter, L. T. (1988) Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 48, 7022-7032.
121. Murayama, O., Nishida, H., and Sekiguchi, K. (1996) Novel peptide ligands for integrin alpha 6 beta 1 selected from a phage display library. J. Biochem. (Tokyo) 120, 445-451.
122. Koivunen, E., Wang, B., and Ruoslahti, E. (1995) Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology (NY) 13, 265-270.
123. Koivunen, E., Restel, B. H., Rajotte, D., Lahdenranta, J., Hagedorn, M., Arap, W., and Pasqualini, R. (1999) Integrin-binding peptides derived from phage display libraries. Methods Mol. Biol. 129, 3-17.
124. Koivunen, E., Arap, W., Valtanen, H., et al. (1999) Tumor targeting with a selective gelatinase inhibitor. Nat. Biotechnol. 17, 768-774.
125. Yanofsky, S. D., Baldwin, D. N., Butler, J. H., et al. (1996) High affinity type I interleukin 1 receptor antagonists discovered by screening recombinant peptide libraries. Proc. Natl. Acad. Sci. USA 93, 7381-7386.
126. Pennington, M. E., Lam, K. S., and Cress, A. E. (1996) The use of a combinatorial library method to isolate human tumor cell adhesion peptides. Mol. Divers, 2, 19-28.
127. Goodson, R. J., Doyle, M. V., Kaufman, S. E., and Rosenberg, S. (1994) High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc. Natl. Acad. Sci. USA 91, 7129-7133.
128. Burg, M. A., Pasqualini, R., Arap, W., Ruoslahti, E., and Stallcup, W. B. (1999) NG2 proteoglycan-binding peptides target tumor neovasculature. Cancer Res. 59, 2869-2874.
129. Sims, D., Horne, M. M., Creighan, M., and Donald, A. (1994) Heterogeneity of pericyte populations in equine skeletal muscle and dermal microvessels: a quantitative study. Anat. Histol. Embryol. 23, 232-238.
130. Lindahl, P., and Betsholtz, C. (1998) Not all myofibroblasts are alike: revisiting the role of PDGF-A and PDGF-B using PDGF-targeted mice. Curr. Opin. Nephrol. Hypertens. 7, 21-26.
131. Hirschi, K. K., and D'Amore, P. A. (1997) Control of angiogenesis by the pericyte: molecular mechanisms and significance. Exs. 79, 419-428.
132. Schrappe, M., Klier, E G., Spiro, R. C., Waltz, T. A., Reisfeld, R. A., and Gladson, C. L. (1991) Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells. Cancer Res. 51, 4986-4993.
133. Leger, O., Johnson-Leger, C., Jackson, E., Coles, B., and Dean, C. (1994) The chondroitin sulfate proteoglycan NG2 is a tumour-specific antigen on the chemically induced rat chondrosarcoma HSN. Int J. Cancer 58, 700-705.
134. Behm, E G., Smith, F. O., Raimondi, S. C., Pui, C. H., and Bernstein, I. D. (1996) Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements. Blood 87, 1134-1139.
135. Scott, J. K., and Smith, G. P. (1990) Searching for peptide ligands with an epitope library. Science 249, 386-390.
136. Collins, J., Horn, N., Wadenback, J., and Szardenings, M. (2001) Cosmix-plexing: a novel recombinatorial approach for evolutionary selection from combinatorial libraries. J. Biotechnol. 74, 317-338.
137. Pasqualini, R., Koivunen, E., and Ruoslahti, E. (1997) Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat. Biotechnol. 15, 542-546.
138. Pinilla, C., Appel, J. R., Borras, E., and Houghten, R. A. (2003) Advances in the use of synthetic combinatorial chemistry: mixture-based libraries. Nat. Med. 9, 118-122.
139. Wrighton, N. C., Balasubramanian, P., Barbone, F. P., et al. (1997) Increased potency of an erythropoietin peptide mimetic through covalent dimerization. Nat. Biotechnol. 15, 1261-1265.
140. Hannon, G. J. (2002) RNA interference. Nature 418, 244-251.
141. Wang, L., Prakash, R. K., Stein, C. A., Koehn, R. K., and Ruffner, D. E. (2003) Progress in the delivery of therapeutic oligonucleotides: organ/cellular distribution and targeted delivery of oligonucleotides in vivo. Antisense Nucleic Acid Drug Dev. 13, 169-189.
142. Czauderna, F., Fechtner, M., Dames, S., et al. (2003) Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 31, 2705-2716.
143. Reed, R. K., Lepsoe, S., and Wiig, H. (1989) Interstitial exclusion of albumin in rat dermis and subcutis in over- and dehydration. Am. J. Physiol. 257, H1819-H1827.
144. Krol, A., Maresca, J., Dewhirst, M. W., and Yuan, F. (1999) Available volume fraction of macromolecules in the extravascular space of a fibrosarcoma: implications for drug delivery. Cancer Res. 59, 4136-4141.
145. Jain, R. K. (1997) Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev. 26, 71-90.
146. Vaupel, P., Kallinowski, F., and Okunieff, P. (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 49, 6449-6465.
147. Jain, R. K. (1988) Determinants of tumor blood flow: a review. Cancer Res. 48, 2641-2658.
148. Hwang, K. M., Fodstad, O., Oldham, R. K., and Morgan, A. C., Jr. (1985) Radiolocalization of xenografted human malignant melanoma by a monoclonal antibody (9.2.27) to a melanoma-associated antigen in nude mice. Cancer Res. 45, 4150-4155.
149. Yang, H. M., and Reisfeld, R. A. (1988) Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice. Proc. Natl. Acad. Sci. USA, 85, 1189-1193.
150. Yang, H. M., and Reisfeld, R. A. (1988) Pharmacokinetics and mechanism of action of a doxorubicin-monoclonal antibody 9.2.27 conjugate directed to a human melanoma proteoglycan. J. Natl. Cancer Inst. 80, 1154-1159.
151. Colapinto, E. V., Zalutsky, M. R., Archer, G. E., et al. (1990) Radioimmunotherapy of intracerebral human glioma xenografts with 1311-labeled F(ab')2 fragments of monoclonal antibody Mel-14. Cancer Res. 50, 1822-1827.
152. Colapinto, E. V., Humphrey, P. A., Zalutsky, M. R., et al. (1988) Comparative localization of murine monoclonal antibody Me1-14 F(ab')2 fragment and whole IgG2a in human glioma xenografts. Cancer Res. 48, 5701-5707.
153. 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Mel-14 F (ab')2-a preliminary report. J. Neurooncol. 24, 109-122.
154. Cokgor, I., Akabani, G., Friedman, H. S., et al. (2001) Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab')(2): a case study. Cancer 91, 1809-1813.
155. Larsen, R. H., Akabani, G., Welsh, P., and Zalutsky, M. R. (1998) The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro. Radiat. Res. 149, 155-162.
156. Makagiansar, I. T., Williams, S., Dahlin-Huppe, K., Fukushi, J., Mustelin, T., and Stallcup, W. B. (2004) Phosphorylation of NG2 proteoglycan by protein kinase C-alpha regulates polarized membrane distribution and cell motility. J. Biol. Chem. 279, 55,262-55,270.
157. Smith, M. R. (2003) Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22, 7359-7368.
158. Lin, C. C., Shen, Y. C., Chuang, C. K., and Liao, S. K. (2001) Analysis of a murine anti-ganglioside GD2 monoclonal antibody expressing both IgG2a and IgG3 isotypes: monoclonality, apoptosis triggering, and activation of cellular cytotoxicity on human melanoma cells. Adv. Exp. Med. Biol. 491, 419-429.
159. Baselga, J., and Albanell, J. (2001) Mechanism of action of anti-HER2 monoclonal antibodies. Ann. Oncol. 12 Suppl 1, S35-S41.